Search Results
Your search for ,WHo matches 20416 pages
Showing 19101 - 19150Inconclusive Outcome for Lapatinib vs Trastuzumab Plus Capecitabine in Preventing CNS Metastases as First Relapse Site in HER2-Positive Breast Cancer
In the phase III CEREBEL study reported in the Journal of Clinical Oncology, Pivot et al compared lapatinib (Tykerb)-capecitabine vs trastuzumab (Herceptin)-capecitabine in the prevention of central nervous system (CNS) metastases as first relapse site in patients with metastatic HER2-positive...
Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011 to 2013
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 found a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by ...
Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer. Treatment outcomes were largely similar for the 17 patients with...
FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) today approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma. Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma. It is...
Classic vs Rare EGFR Mutations in Non–Small Cell Lung Cancer Have Distinct Epidemiology, Clinical Implications
Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis, and poor response to EGFR tyrosine kinase inhibitor therapy, compared with more common, classic EGFR mutations. However, as not all rare mutations are the same, testing and therapy...
Japanese Study Indicates Death at Home Is Better for Terminally Ill Cancer Patients
In a Japanese study reported in the Journal of Clinical Oncology, Kinoshita et al found that death at home vs palliative care units or hospitals was better for terminally ill cancer patients and was not associated with an increased caregiver burden. Study Details The study included two...
Improved Prognosis for Patients With Estrogen Receptor–Positive Breast Cancer With Large Reductions in Mammographic Density After Tamoxifen Initiation
Improved prognosis for women with estrogen receptor–positive breast cancer who experience a large reduction in mammographic density following the initiation of tamoxifen treatment extends to premenopausal as well as postmenopausal women, researchers reported in the Journal of the National...
Sensor Technology May Help Improve the Accuracy of Clinical Breast Exams
Sensor technology has the potential to significantly improve the teaching of proper technique for clinical breast exams, according to a new study by researchers at the University of Wisconsin School of Medicine and Public Health. The results of the study were published in a correspondence in The...
Lower 30-Day Mortality, Increased Likelihood of Chemotherapy With Laparoscopic vs Open Colectomy for Stage III Colon Cancer
“In routine clinical practice, laparoscopic colectomy is associated with lower 30-day mortality, shorter length of stay, and greater likelihood of adjuvant chemotherapy initiation among stage III colon cancer patients when compared with open colectomy,” according to an analysis of data...
Study Shows That Previous Cancer ‘False Alarms’ May Discourage Patients From Screening Future Symptoms
Cancer researchers at University College London (UCL) have found that a cancer false alarm could discourage patients from checking out cancer symptoms they develop in the future. More than 80% of patients with potential cancer symptoms are given the all-clear after investigations. But according to ...
FDA Analysis Explores Relationship Between Response Rate and Survival at Trial and Patient Levels in Advanced NSCLC Studies
In a U.S. Food and Drug Administration (FDA) analysis of randomized trials in advanced non–small cell lung cancer (NSCLC) reported in the Journal of Clinical Oncology, Blumenthal et al found a strong correlation between response rate and progression-free survival at the trial level and a...
FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
Genomic Classifier Score Identifies Risk of Metastasis and Benefit of Adjuvant Radiotherapy After Radical Prostatectomy
In a study reported in the Journal of Clinical Oncology, Den et al found that a 22-biomarker genomic classifier score was predictive of a greater risk of metastasis and benefit of adjuvant vs salvage radiotherapy after radical prostatectomy for prostate cancer. Metastasis Risk The study involved...
Reduction in Late Toxicities With Preoperative Image-Guided Radiation Therapy to Reduced Target Volume in Patients With Extremity Sarcoma
As reported in the Journal of Clinical Oncology by Wang et al, the incidence of late toxicity among patients with extremity soft-tissue sarcoma receiving preoperative image-guided radiotherapy to a reduced target volume in the phase II Radiation Therapy Oncology Group (RTOG) 0630 trial was lower...
12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility
Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...
Early Study Suggests Olaparib May Be Effective in Ovarian Cancers Expressing High Levels of POLQ
Last December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in the treatment of advanced ovarian cancer in women with BRCA1 or BRCA2 gene mutations. Now, a laboratory study by Ceccaldi et al has found that the drug may also be effective in breast and ovarian tumors that...
No Difference in Anxiety or Health-Related Quality of Life in NHL Patients Receiving Rituximab Maintenance vs Retreatment at Disease Progression
In an analysis among patients in the Eastern Cooperative Oncology Group (ECOG) E4402 trial (RESORT) reported in the Journal of Clinical Oncology, Wagner et al found no difference in anxiety or health-related quality of life in patients with low–tumor burden non-Hodgkin lymphoma who received...
Chemotherapy Trials for Advanced Cancers of the Lung and Pancreas Overestimate Survival for Elderly Medicare Patients
Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic cancer and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Lamont et al reported...
Use of Combined-Modality Therapy vs Chemotherapy Alone in Early Hodgkin Lymphoma Affected by Sex, Race, Distance to Treatment, and Insurance
In a study reported in the Journal of Clinical Oncology, Olszewski et al found that numerous factors affected use of combined-modality therapy vs chemotherapy alone in early-stage Hodgkin lymphoma, including sex, race, insurance, and distance to treatment facility. Study Details The study...
ASCO Expresses Concern Over the New CMS Oncology Care Model
On Thursday, February 12, 2015, the U.S. Department of Health and Human Services announced its new Oncology Care Model, a multipayer payment and care delivery model meant to support better health-care coordination for patients with cancer. Although commending the Centers for Medicare & Medicaid ...
FDA Approves Lenvatinib for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
The U.S. Food and Drug Administration (FDA) today granted approval to lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy. Lenvatinib is a tyrosine kinase inhibitor that binds to multiple sites...
Sunitinib Active in Platinum-Refractory Thymic Carcinoma
In a phase II study reported in The Lancet Oncology, Thomas et al found that sunitinib (Sutent) was active in patients with platinum-refractory thymic carcinoma. Study Details In the open-label study, 23 evaluable patients with thymic carcinoma and 16 with thymoma who had disease progression...
Nutrient-Wide Association Study Shows Increased Coffee Intake May Be Associated With Lower Risk of Endometrial Cancer
Women who drank about four cups of coffee per day appeared to have decreased endometrial cancer risk compared with those who drank less than a cup each day, according to a study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention. A New Approach “We used a...
Lenvatinib Shows Promise for Patients With Radioiodine-Refractory Thyroid Cancer in Phase III Study
In a phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral antiangiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. Their findings are published by...
Japanese Phase III Trial Shows No Survival Benefit of First-Line Weekly Cisplatin/Docetaxel vs Docetaxel in Elderly Patients With Advanced NSCLC
In a Japanese phase III trial (Intergroup Trial JCOG0803/WJOG4307L) reported in the Journal of Clinical Oncology, Abe et al found no overall survival benefit of weekly cisplatin/docetaxel vs standard docetaxel in the first-line treatment of elderly patients with advanced non–small cell lung...
Meaning-Centered Group Psychotherapy Improves Psychological Well-Being in Patients With Advanced Cancer
In a randomized trial reported in the Journal of Clinical Oncology, Breitbart et al found that meaning-centered group psychotherapy significantly improved psychological well-being compared with supportive group psychotherapy in patients with advanced or terminal cancer. Meaning-centered group...
Adding Sorafenib to Standard Therapy of No Benefit in Advanced Ovarian Cancer, Study Reveals
In a study of women with stage III/IV epithelial ovarian cancer, the addition of sorafenib (Nexavar) to traditional paclitaxel/carboplatin therapy resulted in no greater efficacy and increased toxicity, according to a report by Hainsworth et al in Cancer Medicine. The investigators suggested that...
Active Smoking Increases Mortality in Nonmetastatic Colorectal Cancer, Both Pre- and Postdiagnosis
In a study reported in the Journal of Clinical Oncology, Yang et al found that current smoking was associated with increased colorectal cancer–specific and all-cause mortality among colorectal cancer patients in both the prediagnosis and postdiagnosis settings. Study Details The study...
Higher Than Expected Incidence of Marrow Neoplasms after Adjuvant Therapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Wolff et al found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy for breast cancer. The study used the National Comprehensive Cancer Network Breast Cancer...
Study Identifies Eight Signs Associated With Impending Death in Cancer Patients
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published by Hui et al in Cancer, could offer clinicians the ability to better communicate with...
ASCO Endorses American Cancer Society Prostate Cancer Survivorship Care Guidelines
The American Society of Clinical Oncology (ASCO) has issued an endorsement of the American Cancer Society's (ACS) Prostate Cancer Survivorship Care Guidelines. These guidelines provide recommendations to primary care physicians on best practices in follow-up care for men after prostate cancer...
New Approach to Colorectal Surgical Care Results in Shorter Recovery Times, Lower Costs
A new, multidisciplinary approach to managing patients undergoing a colorectal operation results in shorter hospital stays, fewer complications, and lower medical costs, according a study published by Thiele et al in the Journal of the American College of Surgeons. Currently, patients undergoing...
Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States
In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...
Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer
Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than standard-of-care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...
Women Who Undergo Delayed Breast Reconstruction May Experience More Cancer‑Related Distress Than Women Who Undergo Mastectomy Alone
In women who have undergone mastectomy, those who underwent delayed breast reconstruction experienced greater cancer-related distress over the long term compared with women who underwent mastectomy alone, according to a prospective study by Metcalfe et al in the Journal of Surgical Oncology. For...
No Reduction in Quality of Life With Addition of Bevacizumab to Chemotherapy in GOG 240 Trial in Advanced Cervical Cancer
The phase III Gynecologic Oncology Group (GOG) 240 trial showed that the addition of bevacizumab (Avastin) to chemotherapy prolonged survival in patients with advanced cervical cancer. An analysis reported in The Lancet Oncology by Penson et al showed no reduction in quality of life among patients...
Omitting Radiotherapy Ups Local Recurrence Risk in Older Women With Low-Risk Breast Cancer After Breast-Conserving Surgery and Endocrine Therapy
In a phase III trial to assess whether whole-breast irradiation could be omitted in women aged ≥ 65 years with early-stage breast cancer undergoing breast-conserving surgery and receiving adjuvant endocrine treatment, Kunkler et al found increased risk of local recurrence in women not receiving...
CMS Issues National Coverage Determination for Screening for Lung Cancer With Low-Dose Computed Tomography
Today the Centers for Medicare & Medicaid Services (CMS) issued a final national coverage determination that provides for Medicare coverage of screening for lung cancer with low-dose computed tomography (CT). The coverage is effective immediately. “This is the first time that Medicare...
Patients With Detectable PSA After Radical Prostatectomy May Benefit From More Aggressive Radiotherapy, 10-Year Post-Treatment Analysis Shows
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
Analysis of Key Breast Cancer Genes Reveals Distinct Profiles for African American, European American Women
Researchers at Roswell Park Cancer Institute (RPCI) have uncovered new information that may begin to explain why many African American women are more likely to be diagnosed with aggressive, often deadly forms of breast cancer. Their findings also strengthen evidence that increased dietary folate...
Phase II Study Shows Activity of Everolimus and Letrozole in Recurrent Endometrial Carcinoma
Interaction of the estrogen receptor and PI3K/AKT/mTOR pathways and the finding of resistance to hormonal therapy mediated by PI3K activation suggest a benefit of adding an mTOR inhibitor to hormonal treatment in endometrial carcinoma. In a phase II study reported in the Journal of Clinical...
Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Perez et al found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who had trastuzumab (Herceptin) added to adjuvant chemotherapy ...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...
Study Sheds New Light on Syndrome Associated With Aggressive Pediatric Cancer
A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never-before- seen flood of mutations in their disease in very short periods of time. The findings were published by Shlien et al in Nature...
Dabrafenib May Stimulate Radioiodine Uptake in Patients With Iodine-Refractory Papillary Thyroid Cancer
In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
Crizotinib Produces Systemic and Intracranial Disease Control in Patients With Advanced ALK-Rearranged NSCLC and Brain Metastases
In a retrospective analysis reported in the Journal of Clinical Oncology, Costa et al found that crizotinib (Xalkori) treatment resulted in high systemic and intracranial disease control rates in patients with ALK-rearranged non–small cell lung cancer (NSCLC) who had asymptomatic brain...
Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...
FDA Grants Priority Review for Trabectedin for the Treatment of Patients With Advanced Soft-Tissue Sarcoma
Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for trabectedin to treat patients with advanced soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have...
California Primary Care Physicians Struggle to Adapt to Breast Density Law, Study Shows
Ten months after California legislators enacted a controversial law mandating that radiologists notify women if they have dense breast tissue, University of California (UC), Davis researchers have found that half of primary care physicians are still unfamiliar with the law, and many don't feel...
